H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics Inc (AXSM – Research Report) yesterday and set a price target of $30.00. The company’s shares closed last Monday at $22.02.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -17.5% and a 22.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Turning Point Therapeutics Inc.
Axsome Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $37.75, which is an 80.4% upside from current levels. In a report issued on October 16, Guggenheim also initiated coverage with a Buy rating on the stock with a $48.00 price target.
The company has a one-year high of $30.50 and a one-year low of $1.94. Currently, Axsome Therapeutics Inc has an average volume of 867.8K.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AXSM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications.